Cutaneous necrosis secondary to terlipressin therapy

Acta Dermato-Venereologica

Volumn 89, Issue 4, 2009, Pages 434-435

  Posada, Celia ^a   Feal, Carlos ^a   García Cruz, Arunzazu ^a   Álvarez, Victoria ^a   Álvarez, Monica ^a   Cruces, Manuel J ^a  

^a Complexo Hospitalario de Pontevedra ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; TERLIPRESSIN;

ADULT; ALCOHOL LIVER CIRRHOSIS; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEPATORENAL SYNDROME; HUMAN; LETTER; LIVER FAILURE; MALE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN NECROSIS; TREATMENT RESPONSE;

ADULT; FATAL OUTCOME; HEPATORENAL SYNDROME; HUMANS; ISCHEMIA; LYSINE VASOPRESSIN; MALE; NECROSIS; SKIN;

EID: 69249100567     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0651     Document Type: Letter

References (9)

1. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006; 24: 935-944. (Pubitemid 44326374)
2. Ginés P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004; 20 Suppl 3: 57-62.
3. Vaccaro F, Giorgi A, Riggio O, De Santis A, Laviano A, Rossi-Fanelli F. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. Dig Liver Dis 2003; 35: 503-506. (Pubitemid 41070445)
4. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews 2006, Issue 4. Art No.: CD005162. DOI: 10.1002/14651858.CD00162.pub2. Available from: http://mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD005162/pdf-fs.html
5. Donnellan F, Cullen G, Hegarty JE, McCormick PA. Ischaemic complications of glypressin in liver disease: a case series. Br J Clin Pharmacol 2007; 64: 550-552. (Pubitemid 47404308)
6. Halimi C, Bonnard P, Bernard B, Matihurin P, Mofredj A, Di Martino V, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-158. (Pubitemid 34163994)
7. Lee JS, Lee HS, Jung SW, Han WS, Kim MJ, Lee SW, et al. [A case of peripherals ischemic complication alter terlipressin therapy]. Korean J Gastroenterol 2006; 47: 454-457 (in Korean).
8. Ortega R, Ginés P, Uriz J, Cárdenas A, Galahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 2002; 36: 941-948.
9. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a restrospective multicenter study. Gastroenterology 2002; 122: 923-930. (Pubitemid 34267275)